

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box 566

In re Application of:  Mary E. Gerritsen et al.  Serial No.: 09/784,810  Filed: 02/14/2001  For: NOVEL SPHINGOSINE KINASES	Examiner: Unknown  Group Art Unit No. 1614
--	--

TRANSMITTAL OF SEQUENCE LISTING

BOX SEQUENCE LISTING

Assistant Commissioner for Patents  
Washington, D.C. 20231

COPY OF PAPERS  
ORIGINALLY FILED


Dear Sir:

Submitted herewith is the following with regard to the above captioned patent application:

- Statement According to 37 C.F.R. § 1.821(f)
- Preliminary Amendment
- Copy of Formalities Letter
- Sequence Listing
- Diskette
- Return Receipt Postcard

Respectfully submitted,


Dated: July 17, 2002

  
Gregory M. Ezaki, Ph.D.  
Registration No. 8,492  
Agent for Applicants

SONNENSCHN NATH & ROSENTHAL  
P.O. Box #061080  
Wacker Drive Station  
Sears Tower  
Chicago, Illinois 60606-1080

Direct line: (312) 876-8936

I hereby certify that this document is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Box Sequence Listing, Assistant Commissioner for Patents, Washington, DC 20231 on July 17, 2002.

  
Joanne Sarantopoulos



COPY OF PAPERS  
ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20503  
WW

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/784,810	02/14/2001	Mary E. Gerritsen	10716/8

28443  
BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, IL 60610

CONFIRMATION NO. 4070

FORMALITIES LETTER



\*OC000000008309537\*

Date Mailed: 06/19/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821 - 1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to: The Office Of Initial Patent Examination.

See the attachment.

**Applicant Must Provide as part of the response:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216

- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice MUST be returned with the reply.*


KLith

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 – COPY TO BE RETURNED WITH RESPONSE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  Mary E. Gerritsen et al.  Serial No.: 09/784,810  Filed: 02/14/2001  For: NOVEL SPHINGOSINE KINASES	  #9 Attention: Manager, Application Branch
--	---

STATEMENT ACCORDING TO 37 C.F.R. § 1.821(f)

**BOX SEQUENCE LISTING**

Assistant Commissioner for Patents  
Washington, D.C. 20231

**COPY OF PAPERS  
ORIGINALLY FILED**


Dear Sir:

Submitted herewith is a sequence listing as part of the above-captioned patent application. Applicants' representative states that the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are the same.

Applicants' representative hereby verifies that the information on the accompanying diskette is identical to the written sequence listing. The enclosed sequence listing does not include any new matter that goes beyond the disclosure in the captioned application as filed.

Respectfully submitted,

Dated: 07/17/2002

  
\_\_\_\_\_  
Gregory M. Zinkl, Ph.D.  
Registration No. 8,492  
Agent for Applicants

SONNENSCHN NATH & ROSENTHAL  
P.O. Box #061080  
Wacker Drive Station  
Sears Tower  
Chicago, Illinois 60606-1080

Direct line: (312) 876-8936